Cargando…
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC. The Netherlands Cancer Regi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898951/ https://www.ncbi.nlm.nih.gov/pubmed/28572122 http://dx.doi.org/10.1183/13993003.01838-2016 |
_version_ | 1783314213108711424 |
---|---|
author | Derks, Jules L. van Suylen, Robert Jan Thunnissen, Erik den Bakker, Michael A. Groen, Harry J. Smit, Egbert F. Damhuis, Ronald A. van den Broek, Esther C. Speel, Ernst-Jan M. Dingemans, Anne-Marie C. |
author_facet | Derks, Jules L. van Suylen, Robert Jan Thunnissen, Erik den Bakker, Michael A. Groen, Harry J. Smit, Egbert F. Damhuis, Ronald A. van den Broek, Esther C. Speel, Ernst-Jan M. Dingemans, Anne-Marie C. |
author_sort | Derks, Jules L. |
collection | PubMed |
description | Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC. The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003–2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as “NSCLC-t”, comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; “NSCLC-pt”, with pemetrexed treatment only; and “SCLC-t”, consisting of etoposide chemotherapy. A panel review diagnosis of LCNEC was established in 128 out of 207 patients. NSCLC-t chemotherapy was administered in 46% (n=60), NSCLC-pt in 16% (n=20) and SCLC-t in 38% (n=48) of the patients. The median (95% CI) overall survival for NSCLC-t chemotherapy was 8.5 (7.0–9.9) months, significantly longer than patients treated with NSCLC-pt, with a median survival of 5.9 (5.0–6.9) months (hazard ratio 2.51, 95% CI 1.39–4.52; p=0.002) and patients treated with SCLC-t chemotherapy, with a median survival of 6.7 (5.0–8.5) months (hazard ratio 1.66, 95% CI 1.08–2.56; p=0.020). In patients with LCNEC, NSCLC-t chemotherapy results in longer overall survival compared to NSCLC-pt and SCLC-t chemotherapy. |
format | Online Article Text |
id | pubmed-5898951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-58989512018-04-18 Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Derks, Jules L. van Suylen, Robert Jan Thunnissen, Erik den Bakker, Michael A. Groen, Harry J. Smit, Egbert F. Damhuis, Ronald A. van den Broek, Esther C. Speel, Ernst-Jan M. Dingemans, Anne-Marie C. Eur Respir J Original Articles Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC. The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003–2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as “NSCLC-t”, comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; “NSCLC-pt”, with pemetrexed treatment only; and “SCLC-t”, consisting of etoposide chemotherapy. A panel review diagnosis of LCNEC was established in 128 out of 207 patients. NSCLC-t chemotherapy was administered in 46% (n=60), NSCLC-pt in 16% (n=20) and SCLC-t in 38% (n=48) of the patients. The median (95% CI) overall survival for NSCLC-t chemotherapy was 8.5 (7.0–9.9) months, significantly longer than patients treated with NSCLC-pt, with a median survival of 5.9 (5.0–6.9) months (hazard ratio 2.51, 95% CI 1.39–4.52; p=0.002) and patients treated with SCLC-t chemotherapy, with a median survival of 6.7 (5.0–8.5) months (hazard ratio 1.66, 95% CI 1.08–2.56; p=0.020). In patients with LCNEC, NSCLC-t chemotherapy results in longer overall survival compared to NSCLC-pt and SCLC-t chemotherapy. European Respiratory Society 2017-06-01 /pmc/articles/PMC5898951/ /pubmed/28572122 http://dx.doi.org/10.1183/13993003.01838-2016 Text en Copyright ©ERS 2017 http://creativecommons.org/licenses/by-nc/4.0/ This ERJ Open article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Original Articles Derks, Jules L. van Suylen, Robert Jan Thunnissen, Erik den Bakker, Michael A. Groen, Harry J. Smit, Egbert F. Damhuis, Ronald A. van den Broek, Esther C. Speel, Ernst-Jan M. Dingemans, Anne-Marie C. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
title | Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
title_full | Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
title_fullStr | Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
title_full_unstemmed | Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
title_short | Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
title_sort | chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898951/ https://www.ncbi.nlm.nih.gov/pubmed/28572122 http://dx.doi.org/10.1183/13993003.01838-2016 |
work_keys_str_mv | AT derksjulesl chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT vansuylenrobertjan chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT thunnissenerik chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT denbakkermichaela chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT groenharryj chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT smitegbertf chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT damhuisronalda chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT vandenbroekestherc chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT speelernstjanm chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT dingemansannemariec chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter AT chemotherapyforpulmonarylargecellneuroendocrinecarcinomasdoestheregimenmatter |